Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperacillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | CCKBR | P32239 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | FPR1 | P21462 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperacillin SCHEMBL10956851 | 1.00 | LMNA (0.78) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL34180 | 1.00 | LMNA (0.78) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL536988 | 1.00 | LMNA (0.78) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL9374347 | 1.00 | LMNA (0.78) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL1665895 | 0.99 | LMNA (0.77) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL11045258 | 0.98 | LMNA (0.76) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL11045255 | 0.98 | LMNA (0.76) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL10692696 | 0.98 | LMNA (0.75) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL24437361 | 0.93 | MEN1 (0.77) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL33894 | 0.93 | MEN1 (0.77) | LMNAKMT2AMEN1CCKBRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293488-A1 | COMPOSITIONS AND METHODS OF USE OF ANTIBACTERIAL DRUG COMBINATIONS | UNIVERSITY OF NOTRE DAME DU LAC | 2023-09-21 | — | — | US | disclosed |
| CN-111939157-B | Application of omeprazole sodium for injection in preventing and treating aspiration pneumonia caused by gastric acid reflux | 山东和兴药业有限公司 | 2023-06-20 | — | — | CN | disclosed |
| US-11559514-B2 | Compositions and methods of use of antibacterial drug combinations | WASHINGTON UNIVERSITY (US) | 2023-01-24 | — | — | US | disclosed |
| EP-4112057-A1 | COMPOSITIONS AND METHODS OF USE OF ANTIBACTERIAL DRUG COMBINATIONS | Washington University (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-114796499-A | Compositions and methods of use of antibacterial drug combinations | 华盛顿大学 | 2022-07-29 | — | — | CN | disclosed |
| EP-3319609-B1 | COMPOSITIONS AND METHODS OF USE OF ANTIBACTERIAL DRUG COMBINATIONS | UNIV WASHINGTON (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-108289896-B | Compositions and methods of use of antibacterial drug combinations | 华盛顿大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-111939157-A | Application of omeprazole sodium for injection in preventing and treating aspiration pneumonia caused by gastric acid reflux | 山东和兴药业有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-20200054605-A1 | COMPOSITIONS AND METHODS OF USE OF ANTIBACTERIAL DRUG COMBINATIONS | UNIVERSITY OF NOTRE DAME DU LAC | 2020-02-20 | — | — | US | disclosed |
| US-20180200226-A1 | COMPOSITIONS AND METHODS OF USE OF ANTIBACTERIAL DRUG COMBINATIONS | UNIVERSITY OF NOTRE DAME DU LAC | 2018-07-19 | — | — | US | disclosed |
| WO-2006113914-A2 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1689228-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | Fred Hutchinson Cancer Research Center (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1684579-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1684580-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-08-04 | — | — | US | disclosed |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-07-07 | — | — | US | disclosed |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-23 | — | — | US | disclosed |
| WO-2005041655-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041656-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005039291-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | HIF1A, HIF1AN, PYGL | LMNA 3777/4885KMT2A 3659/4885MEN1 3603/4885 |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HSF1, HSP90AB1, HSP90AA1 | LMNA 3148/4885KMT2A 4195/4885MEN1 1842/4885 |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | PLAT, TBXA2R, THPO | LMNA 884/4885KMT2A 2838/4885MEN1 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.